VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement (“CTA”) with Yale University (“Yale”) for the investigation of multiple intravenous…


Previous articleBeckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
Next articleVariants in 5-HT2A Receptor Gene Alter Psychedelic Pharmacology